Compare Plug Power Inc (PLUG) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Plug Power Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? Plug Power Inc trades at $1.42 (market cap $2.18B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 2.2× Plug Power Inc's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, Plug Power Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Plug Power Inc for 42 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| PLUG | TVTX | |
|---|---|---|
Market Cap | $2.18B | $4.88B |
Volume | 58,569,311 | 1,668,577 |
Sector | Industrials | Health |
52-Week High | $4.14 | $67.52 |
52-Week Low | $1.45 | $26.79 |
Typical Hold Time | 42 Days | 0 Days |
Enterprise Value | $3.05B | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Plug Power (PLUG) trades at $1.45, down 10.49% today, reflecting ongoing operational challenges. The stock shows bearish technical signals with negative moving averages, while fundamentals reveal persistent losses with a -220.59% net income margin and negative cash flow. Recent news highlights strategic partnerships including a 280 MW electrolyzer agreement with Arcadia eFuels, but the company continues to miss earnings expectations consistently.
Despite analyst consensus favoring Buy ratings (44.73%), PLUG faces significant execution risks with negative profitability and high cash burn. The $3.33 price target suggests potential upside if green hydrogen adoption accelerates, but investors must weigh substantial operational losses against long-term growth prospects in the clean energy sector.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Plug Power Inc
Plug Power is building an end-to-end green hydrogen ecosystem—from production, storage and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets—including material handling, e-mobility, power generation, and industrial applications.
Read more on PLUG →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
